RecruitingPhase 1NCT07728942

SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors

A Phase 1 Study of the Antibody-Radionuclide Conjugate SLR-108 for Positron Emission Tomography Imaging in Subjects With Metastatic Solid Tumors

Sponsor

Solve Therapeutics

Enrollment

70 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Solid Tumors

Summary

This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SLR-108 and a drug called SLX-1411 for people with metastatic solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.